Statins & risk of
Clostridium difficile
HMG-CoA reductase inhibitors
meta-analysis
statins
Journal
The Indian journal of medical research
ISSN: 0971-5916
Titre abrégé: Indian J Med Res
Pays: India
ID NLM: 0374701
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
entrez:
12
12
2019
pubmed:
12
12
2019
medline:
12
5
2020
Statut:
ppublish
Résumé
Clostridium difficile infection is one of the most common healthcare-associated infections worldwide. Recent epidemiologic studies have suggested that statin users may have a lower risk of C. difficile infection, although the results are inconsistent. This meta-analysis was conducted with the aim of summarizing all available data to assess the risk of C. difficile infection among statin users versus non-users. A literature review was performed using the MEDLINE and EMBASE databases from inception to October 2017. Cohort, case-control and cross-sectional studies that compared the risk of C. difficile infection among statin users versus non-users were included. Pooled odds ratio (OR) and 95 per cent confidence interval (CI) were calculated using a random-effect, generic inverse variance method. Six case-control studies and two cross-sectional studies met the eligibility criteria and were included in this meta-analysis. The risk of C. difficile infection among statin users was significantly lower than non-users with the pooled OR of 0.74 (95% CI, 0.61-0.89). The statistical heterogeneity of this study was high (I This meta-analysis demonstrated a decreased risk of C. difficile infection among statin users versus non-users. Further studies are required to clarify the role of statins for prevention of C. difficile infection in clinical practice.
Sections du résumé
Background & objectives
Clostridium difficile infection is one of the most common healthcare-associated infections worldwide. Recent epidemiologic studies have suggested that statin users may have a lower risk of C. difficile infection, although the results are inconsistent. This meta-analysis was conducted with the aim of summarizing all available data to assess the risk of C. difficile infection among statin users versus non-users.
Methods
A literature review was performed using the MEDLINE and EMBASE databases from inception to October 2017. Cohort, case-control and cross-sectional studies that compared the risk of C. difficile infection among statin users versus non-users were included. Pooled odds ratio (OR) and 95 per cent confidence interval (CI) were calculated using a random-effect, generic inverse variance method.
Results
Six case-control studies and two cross-sectional studies met the eligibility criteria and were included in this meta-analysis. The risk of C. difficile infection among statin users was significantly lower than non-users with the pooled OR of 0.74 (95% CI, 0.61-0.89). The statistical heterogeneity of this study was high (I
Interpretation & conclusions
This meta-analysis demonstrated a decreased risk of C. difficile infection among statin users versus non-users. Further studies are required to clarify the role of statins for prevention of C. difficile infection in clinical practice.
Identifiants
pubmed: 31823917
pii: IndianJMedRes_2019_150_4_359_272094
doi: 10.4103/ijmr.IJMR_1973_17
pmc: PMC6902370
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
359-364Déclaration de conflit d'intérêts
None
Références
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Nat Med. 2000 Dec;6(12):1399-402
pubmed: 11100127
Am J Med. 2011 Mar;124(3):276.e1-7
pubmed: 21396512
Curr Pharm Des. 2012;18(11):1519-30
pubmed: 22364136
Infect Drug Resist. 2018 Mar 13;11:405-416
pubmed: 29559802
JAMA. 2007 Apr 4;297(13):1455-64
pubmed: 17405971
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
J Antimicrob Chemother. 2013 Aug;68(8):1889-93
pubmed: 23563740
Clin Cardiol. 2016 Sep;39(9):491-6
pubmed: 27505443
J Virol. 2004 Nov;78(21):12062-5
pubmed: 15479847
Am J Physiol Gastrointest Liver Physiol. 2017 May 1;312(5):G488-G497
pubmed: 28209601
Infect Immun. 2004 Feb;72(2):1036-42
pubmed: 14742551
Am J Respir Crit Care Med. 2009 Jun 15;179(12):1107-14
pubmed: 19324974
Indian J Pathol Microbiol. 2017 Apr-Jun;60(2):221-225
pubmed: 28631639
Saudi Med J. 2013 May;34(5):477-83
pubmed: 23677263
Infect Control Hosp Epidemiol. 2011 Apr;32(4):387-90
pubmed: 21460491
Drugs. 2013 Oct;73(15):1681-709
pubmed: 24114622
Front Med (Lausanne). 2018 Feb 08;5:24
pubmed: 29473041
Gut. 2012 Nov;61(11):1538-42
pubmed: 22442166
Pharmacotherapy. 2009 Jun;29(6):621-30
pubmed: 19476415
Infect Control Hosp Epidemiol. 2015 Dec;36(12):1409-16
pubmed: 26387888
Ann Intern Med. 2006 Nov 21;145(10):758-64
pubmed: 17116920
BMC Public Health. 2013 Feb 19;13:154
pubmed: 23421987
J Clin Gastroenterol. 2004 Jul;38(6):475-83
pubmed: 15220681
N Engl J Med. 2015 Feb 26;372(9):825-34
pubmed: 25714160
J Clin Med. 2016 Oct 11;5(10):
pubmed: 27727158
Aliment Pharmacol Ther. 2013 Sep;38(6):619-27
pubmed: 23888883
Eur J Clin Microbiol Infect Dis. 2016 May;35(5):779-84
pubmed: 26864041
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120